SAN DIEGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a multi-year technology and discovery collaboration agreement with Takeda that will use Iambic’s industry leading AI drug discovery models to advance a select set of high-priority small molecule programs, initially in Takeda’s Oncology and Gastrointestinal and Inflammation therapeutic areas.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
